Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 3
1997 6
1998 12
1999 18
2000 38
2001 35
2002 26
2003 24
2004 33
2005 27
2006 27
2007 26
2008 18
2009 16
2010 18
2011 18
2012 13
2013 16
2014 12
2015 12
2016 12
2017 8
2018 7
2019 6
2020 5
2021 4
2022 3
2023 5
2024 11
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Yang CP, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544. JAMA Netw Open. 2021. PMID: 34633423 Free PMC article.
IMPORTANCE: New therapeutic classes of migraine-specific treatment have been developed, including 5-hydroxytryptamine1F receptor agonists (lasmiditan) and calcitonin gene-related peptide antagonists (rimegepant and ubrogepant). ...Lasmiditan was associated with the highest …
IMPORTANCE: New therapeutic classes of migraine-specific treatment have been developed, including 5-hydroxytryptamine1F receptor agon …
Acute Migraine Treatment in Adults.
Becker WJ. Becker WJ. Headache. 2015 Jun;55(6):778-93. doi: 10.1111/head.12550. Epub 2015 Apr 15. Headache. 2015. PMID: 25877672 Review.
Acetaminophen, 4 nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, acetylsalicylic acid [ASA], naproxen sodium, and diclofenac potassium), and 7 triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan) have good evid …
Acetaminophen, 4 nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, acetylsalicylic acid [ASA], naproxen sodium, and diclofenac potas …
Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Cameron C, et al. Headache. 2015 Jul-Aug;55 Suppl 4:221-35. doi: 10.1111/head.12601. Epub 2015 Jul 14. Headache. 2015. PMID: 26178694 Review.
Among individual triptans, sumatriptan subcutaneous injection, rizatriptan ODT, zolmitriptan ODT, and eletriptan tablets were associated with the most favorable outcomes. ...
Among individual triptans, sumatriptan subcutaneous injection, rizatriptan ODT, zolmitriptan ODT, and eletriptan tablets were associa …
Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Karlsson WK, Ostinelli EG, Zhuang ZA, Kokoti L, Christensen RH, Al-Khazali HM, Deligianni CI, Tomlinson A, Ashina H, Ruiz de la Torre E, Diener HC, Cipriani A, Ashina M. Karlsson WK, et al. BMJ. 2024 Sep 18;386:e080107. doi: 10.1136/bmj-2024-080107. BMJ. 2024. PMID: 39293828 Free PMC article.
In head-to-head comparisons between active interventions, eletriptan was the most effective drug for pain freedom at two hours (odds ratios from 1.46 (1.18 to 1.81) to 3.01 (2.13 to 4.25)), followed by rizatriptan (1.59 (1.18 to 2.17) to 2.44 (1.75 to 3.45)), sumatriptan ( …
In head-to-head comparisons between active interventions, eletriptan was the most effective drug for pain freedom at two hours (odds ratios …
The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.
Marmura MJ, Silberstein SD, Schwedt TJ. Marmura MJ, et al. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499. Headache. 2015. PMID: 25600718 Review.
The specific medications - triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan [oral, nasal spray, injectable, transcutaneous patch], zolmitriptan [oral and nasal spray]) and dihydroergotamine (nasal spray, inhaler) are effective (Level A …
The specific medications - triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan [oral, nasal spray, …
Rizatriptan: an update of its use in the management of migraine.
Wellington K, Plosker GL. Wellington K, et al. Drugs. 2002;62(10):1539-74. doi: 10.2165/00003495-200262100-00007. Drugs. 2002. PMID: 12093318 Review.
Rizatriptan is generally well tolerated and adverse events are usually mild and transient. ...Although well designed studies comparing rizatriptan with almotriptan, eletriptan and frovatriptan would further define the position of rizatriptan, current data sug …
Rizatriptan is generally well tolerated and adverse events are usually mild and transient. ...Although well designed studies comparin …
Rizatriptan as an Over-the-Counter Triptan in the Treatment of Migraine Attacks.
Göbel CH, Heinze A, Cirkel A, Göbel H. Göbel CH, et al. Pain Ther. 2024 Aug;13(4):813-827. doi: 10.1007/s40122-024-00625-2. Epub 2024 Jun 17. Pain Ther. 2024. PMID: 38886287 Free PMC article. Review.
The lowest approved dose of rizatriptan is 5 mg. This was investigated in three randomized controlled trials with 752 patients. ...There was no significant difference in the frequency of adverse events with rizatriptan 5 mg compared to placebo. Rizatriptan 5 …
The lowest approved dose of rizatriptan is 5 mg. This was investigated in three randomized controlled trials with 752 patients. ...Th …
Rizatriptan in migraine.
Krymchantowski AV, Bigal ME. Krymchantowski AV, et al. Expert Rev Neurother. 2005 Sep;5(5):597-603. doi: 10.1586/14737175.5.5.597. Expert Rev Neurother. 2005. PMID: 16162083 Review.
However, they differ with regard to several of their clinical parameters, including onset of relief and consistency of response. Rizatriptan is a selective agonist of the 5-hydroxytryptophan(1B/1D )receptors, with proven superiority over placebo, ergotamine and selected or …
However, they differ with regard to several of their clinical parameters, including onset of relief and consistency of response. Rizatrip …
Comparison table: Triptans.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-e99. doi: 10.58347/tml.2023.1678b. Med Lett Drugs Ther. 2023. PMID: 37266988 No abstract available.
Rizatriptan: a review of its efficacy in the management of migraine.
Dooley M, Faulds D. Dooley M, et al. Drugs. 1999 Oct;58(4):699-723. doi: 10.2165/00003495-199958040-00013. Drugs. 1999. PMID: 10551439 Review.
In general, rizatriptan 10 mg appeared to be more effective than rizatriptan 5 mg. However, recurrence rates with rizatriptan 5 and 10 mg appeared to be similar to those with placebo. ...Rizatriptan 10 mg appears to be more effective than rizatripta …
In general, rizatriptan 10 mg appeared to be more effective than rizatriptan 5 mg. However, recurrence rates with rizatript …
432 results